CCM
DNLI icon

Coldstream Capital Management’s Denali Therapeutics DNLI Stock Holding History

Coldstream Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-145
Closed -$1.97K – 1715
2025
Q1 		$1.97K Buy
+145
New +$2.78K ﹤0.01% 3003

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coldstream Capital Management's DNLI Position: Q2 2025 in Review

Coldstream Capital Management sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 145 shares — an estimated $1.97K sold.

Coldstream Capital Management first reported a position in DNLI in Q1 2025 and held it in 1 quarter. The position peaked at $1.97K in Q1 2025. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Coldstream Capital Management reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 145 Denali Therapeutics shares in Q2 2025, an estimated $1.97K.
  • Coldstream Capital Management first reported a position in Denali Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Denali Therapeutics position peaked at $1.97K in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.